[{"address1": "100 Summer Street", "address2": "Suite 2300", "city": "Boston", "state": "MA", "zip": "02110", "country": "United States", "phone": "617 621 7722", "fax": "617 494 0480", "website": "https://www.ironwoodpharma.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 267, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas A. McCourt", "age": 66, "title": "CEO & Director", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 1609015, "exercisedValue": 46816, "unexercisedValue": 415410}, {"maxAge": 1, "name": "Mr. John  Minardo", "age": 47, "title": "Senior VP, Chief Legal Officer & Secretary", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 814406, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Shetzline M.D., Ph.D.", "age": 64, "title": "Chief Medical Officer, Senior VP and Head of Research & Drug Development", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 860450, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Davis", "age": 36, "title": "Senior VP & Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2023, "totalPay": 824360, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ronald  Silver", "age": 40, "title": "Corporate Controller & Principal Accounting Officer", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Greg  Martini", "title": "Vice President of Strategic Finance & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mike  Nanfito", "title": "Vice President of Sales & Sales Excellence", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Susanna Y. Huh M.D., M.P.H.", "title": "VP & Head of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jana  Noeldeke", "title": "Basel Site Head & Apraglutide Lifecycle Leader", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Roache", "title": "Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 1, "compensationRisk": 2, "shareHolderRightsRisk": 6, "overallRisk": 3, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.98, "open": 5.0, "dayLow": 4.88, "dayHigh": 5.045, "regularMarketPreviousClose": 4.98, "regularMarketOpen": 5.0, "regularMarketDayLow": 4.88, "regularMarketDayHigh": 5.045, "beta": 0.489, "trailingPE": 62.0, "forwardPE": 11.5348835, "volume": 2991398, "regularMarketVolume": 2991398, "averageVolume": 2249493, "averageVolume10days": 1604880, "averageDailyVolume10Day": 1604880, "bid": 4.93, "ask": 4.97, "bidSize": 900, "askSize": 300, "marketCap": 792305472, "fiftyTwoWeekLow": 3.79, "fiftyTwoWeekHigh": 15.7, "priceToSalesTrailing12Months": 1.9779699, "fiftyDayAverage": 5.8662, "twoHundredDayAverage": 8.8564, "currency": "USD", "enterpriseValue": 1330232192, "profitMargins": 0.023, "floatShares": 131891701, "sharesOutstanding": 159739008, "sharesShort": 14003568, "sharesShortPriorMonth": 16848625, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0877, "heldPercentInsiders": 0.01687, "heldPercentInstitutions": 1.0963401, "shortRatio": 6.18, "shortPercentOfFloat": 0.1697, "bookValue": -2.014, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": 9212000, "trailingEps": 0.08, "forwardEps": 0.43, "pegRatio": 0.29, "lastSplitFactor": "1194:1000", "lastSplitDate": 1554163200, "enterpriseToRevenue": 3.321, "enterpriseToEbitda": 10.998, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "IRWD", "underlyingSymbol": "IRWD", "shortName": "Ironwood Pharmaceuticals, Inc.", "longName": "Ironwood Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1265207400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "bbecc65d-4c04-3cd5-be4a-aec950ecb433", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.96, "targetHighPrice": 23.0, "targetLowPrice": 4.0, "targetMeanPrice": 12.5, "targetMedianPrice": 12.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 105524000, "totalCashPerShare": 0.661, "ebitda": 120957000, "totalDebt": 640256000, "quickRatio": 3.596, "currentRatio": 3.915, "totalRevenue": 400564992, "revenuePerShare": 2.549, "returnOnAssets": 0.14932, "freeCashflow": 97395504, "operatingCashflow": 146743008, "revenueGrowth": -0.121, "grossMargins": 0.67954004, "ebitdaMargins": 0.30197, "operatingMargins": 0.29073, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]